Target Market Focus on clinical-stage biotech and specialty allergen players seeking patient-friendly therapeutic platforms, particularly those pursuing food allergy indications and mucosal immunotherapies, to align Intrommune’s OMIT approach with their portfolio expansion.

Strategic Partnerships Opportunity to engage with contract research organizations, pharmaceutical collaborators, and academic-industry alliances to advance OMEGA Phase 1 data into larger trials, co-development deals, or licensing arrangements leveraging Intrommune’s toothpaste-based delivery model.

Clinical Momentum Leverage recent trial updates and conference presentations to create interest around safety and exploratory efficacy signals, positioning as a catalyst for strategic investments, joint ventures, or milestone-based partnerships.

Regulatory Narratives Highlight the uniquely convenient daily-use delivery platform as a differentiator in regulatory discussions, with potential for faster patient adherence metrics and real-world data opportunities that appeal to investors and payers.

Market Expansion Identify opportunities in adjacent allergic disease areas and consumer health channels (dental/oral care segments) that could benefit from a similar oral mucosal immunotherapy approach, enabling cross-selling or portfolio diversification.